As part of our ongoing aim to bring you reports of innovative developments, we have added a review of the recent SUNSHINE and SUNRISE trials which explored the use of secukinumab in moderate-to-severe hidradenitis suppurativa.
Independent commentary is provided by Associate Professor Erin McMeniman, a Dermatologist practicing in both public and private practice in Brisbane.
Please login below to download this issue (PDF)